Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

es that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.

Accounting policies

Basis of accounting

The condensed interim financial statement for the period ended June 30, 2008 has been prepared in accordance with IAS 34, 'interim financial reporting'. The accounting policies are consistent with those of the annual financial statements for the year ended December 31, 2007, as described in the annual financial statements for the year ended December 31, 2007.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...Newswire-FirstCall/ -- Spherix Incorporated (Nasda...etes therapy, and a provider of technical and regu...otechnology and pharmaceutical companies, today an... Shareholders. ,, At the meeting, shareholders ...he following members to the Board of Directors: ,...
(Date:11/19/2009)...ovember 19 MONITORING FORCE GmbH,a...09 Flibanserin in the,indication treatment-relevan...se for orphan drug status designation with the Eur...skinesia is a complication of the mainstay,treatme... some of those,affected, since it may be disabling...
(Date:11/19/2009)...urgeons and recognized refractive and cataract sur... brought their fellow surgeons up-to-date on the l...ataract surgery, and ophthalmology in general at t...ology (AAO) annual meeting in San Francisco, Calif...Dr. David Huang, MD, Dr. Randy Epstein, Dr. Willia...
(Date:11/19/2009)...honored by latest award for revolutionary hearing ... November 16, 2009 -- Popular Science Magazine has...id from InSound Medical a winner of its coveted Be...y.    Chosen from thousands of... hearing canal for up to four months while providi...
Breaking Biology Technology:Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
... Texas, May 27 Lexicon Pharmaceuticals, Inc. (...sed on discovering and developing breakthrough tre...e company will be giving oral presentations on two... LX1031 , an oral drug candidate for the treatm...X1032 , an oral drug candidate for managing gastr...
...Calif., May 27 Cord Blood America, Inc. (OTC Bull...ell preservation company ( http://www.cordblood-...ng potential of stem cells to families nationwide ...d its secured debt by a total of $4.194 million in...th, 2009, Cord Blood America announced it had decr...
... Microbia, Inc. (formerly Microbia Preci...ction of sustainable, specialty ingredients and bi... that Alex Chu has joined the company as vice pres...vice president of manufacturing and process develo...bia,s process development and manufacturing initia...
Other Biology Technology:Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week 2Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week 3Cord Blood America Says Debt Reduced $4.194 Million in 2009 2Microbia, Inc. Names Alex Chu as Vice President of Process Development 2
(Date:11/23/2009)...dangers to human health and the environment. North...ect with funding from the U.S. Environmental Prote... that contribute to millions of overflows every ye...her reduce the risk of sewage spills. , At issue...pposed to "combined" systems that also handle stor...
(Date:11/23/2009)..., Of all global carbon dioxide emissions, less th...ributes to global warming. The remainder is hidden... forests, grasslands and peat-lands. Stimulating t...ystems is considered one of the main, immediately ..., new greenhouse gas bookkeeping has revealed that...
(Date:11/22/2009)...have succeeded in producing the polymers used for ...han through the use of fossil fuel based chemicals...w for the production of environmentally conscious ...l Biotechnology and Bioengineering to mark the j...ules found in everyday life in the form of plastic...
Breaking Biology News(10 mins):Lose the fat: Targeting grease to curtail sewer overflows 2Intensive land management leaves Europe without carbon sinks 2Bioengineers succeed in producing plastic without the use of fossil fuels 2FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 1FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 2FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 4FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 5FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 6FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 7HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 1HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 4Young Ballerinas May Face Heart Bone Risks 47452 1
...o more cardiac genes to the list of potential link...ng the possibility that genetic defects of the hea...research will be presented Friday at Heart Rhythm ...eart Rhythm Society in Boston. , In the two recent... (CAV3) and the cardiac ryanodine receptor (RyR2) ...
... could now be as easy as flipping a molecular ligh...stitute have created an "optically switchable" mat... exposed to ultraviolet (UV) light. The new materi... journal Angewandte Chemie International Edition, ...protein filter for biological mixtures to a tiny v...
...ke up while hibernating may be an evolutionary mec...researchers at Penn State. The finding could offer...tious disease in wildlife, and has potential impli...nimals slip into an inert sleep-like state as part...en food supplies are low and the need for energy t...
Other Biology News:Researchers link two more genes to sudden infant death syndrome 2Sticky surfaces turn slippery with the flip of a molecular light switch 2Breaks in hibernation help fight bugs 2
Agencourt SPRPlate D - Disc Magnet Plate from Agencourt Bioscience
Nunc OmniTray from Sigma-Aldrich
...novel disposable spin filtration device especially...sates in plasmid purification procedures. , ...n filtration device especially designed to aid the...ification procedures. The neutralized lysate is ce...
...ding) polystyrene surface is hydrophobic in nature...ns,• Is suitable primarily for the immobiliza...have large hydrophobic regions that can interact w...mately 250 ng of mouse IgG/cm2,• EIA/RIA plat...
Biology Products: